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According to contemporary epidemiological and experimental evidence, we propose a novel classification of
cancers based on pathogenesis instead of classifications based on histological appearance of cancer. This new
scheme first defines cancers as either 1. inborn errors of development or 2. sporadic ones, and then sub-defines the
former into 1A. inborn inherited errors of development, being those due to mutations contributed by one or both
parents’ gametes to the developing conceptus, and 1B. inborn induced errors of development when the
malformations and/or cancers are due to environmental carcinogenic exposure during pregnancy. It is anticipated
that the origin of an increasing number of so-called sporadic cancers will turn out to be linked to the inborn
induced errors of development group.
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Human cancers have been classified according to diverse
criteria primarily to serve the needs of the medical pro-
fession to diagnose, stage, prognosticate and treat the
disease. aFor these pragmatic purposes, pathological clas-
sifications of cancer are based on organ of origin of the
tumor and predominant cell type (epithelial or mesenchy-
mal), with a long list of sub-classifications including (but
not limited to) whether the tumor is benign or malignant
(e.g., adenoma vs. carcinoma; fibroma vs. sarcoma), encap-
sulated or invasive, whether it contains components of
different cell types or tissues (e.g., “desmoplastic adeno-
carcinoma”), and whether it displays low or high prolif-
eration rates (mitotic indices). In recent years, a major
effort has been devoted to characterize tumors based on
their molecular features, particularly referring to genetic
mutations and/or patterns of gene expression. Prognostic
and therapeutic advances based on molecular features in-
cluded, for example, identifying the estrogen and proges-
terone receptor and HER2/Neu status of breast cancers,
or the mutational status of gastric stromal sarcomas and
response to Gleevec [1]. The correlation between genomic
somatic mutations in cells of “sporadic” cancers with a
specific targeted therapy has been interpreted as being
causal. However, according to recent pronouncements by
the very proponents of such theoretical links, successes* Correspondence: carlos.sonnenschein@tufts.edu
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article, unless otherwise stated.have been disappointing [2-5]. Admittedly, cancers are
complex biological phenomena whose full understand-
ing remains incomplete [3,6].
Regardless of whether carcinogenesis represents either
a cell-based [3] or a tissue-based [6,7] phenomenon, from
an etiopathogenic perspective, two main types of cancers
are apparent: they can either be inherited or “sporadic”.
Inherited cancers refer to those cancers that have an obvi-
ous or suspected link to germ-line mutations present in
chromosomes that are passed on from one generation to
the next. Sporadic cancers refer to those cancers that are
assumed to lack an obvious inherited component; instead,
it has been proposed that they are the result of the life-
long accumulation of spontaneous or induced mutations
in a single “normal” cell. Again, this classification does not
address whether the cancer process is initiated within a
cell as Boveri [8], Nowell [9] and most others have favored
since the 20th century, or instead, at the tissue level [10].
Theories of carcinogenesis and metastases
There are divergent opinions regarding the level of bio-
logical organization at which cancer originates. The so-
matic mutation theory of carcinogenesis (SMT) defines
cancer as a cell-based disease [8,9,11]. Its fundamental
premise is that cancer is due to the accumulation of spon-
taneous or induced somatic mutations and/or chromo-
somal aberrations that alter the control of proliferation
in a single cell that eventually will generate a tumor
[8,12,13]. Boveri called this cell “the cancer cell” [8] andCentral Ltd. This is an Open Access article distributed under the terms of the
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[14]. In this context, cancer becomes a clonal disease
[9]. A seldom mentioned additional premise associated
to SMT has been that quiescence rather than proliferation
is the default state of cells in multicellular organisms
[15-17]. Adoption of this latter premise implies that cells
need to be stimulated directly in order to proliferate; fol-
lowing this rationale, since the 1950s, “growth factors”
and, since the 1980s, oncogenes have been proposed as
stimulators of cell proliferation [15,18].
From the second half of the 20th century onward,
SMT gained standing due to staggering advances in gen-
etics and molecular biology, and the de-emphasizing of
physiology and developmental biology in cancer patho-
genesis. The initial claim that cancers were due to a sin-
gle mutation in a cell in culture conditions [19], referred
to as malignant transformation, was followed by claims
that the number of somatic mutations responsible for
such a transformation in human tumors increased from
single digits to the thousands [20,21]. Eventually, the
SMT morphed from its original simplicity into the 6
“hallmarks of cancer” in 2000 [11], with 2 more being
added a decade later [22].
In contrast to the SMT, the tissue organization field
theory of carcinogenesis (TOFT) posits that cancer is i)
a tissue-based disease, and that, explicitly, ii) prolifera-
tion is the default state of all cells [10]. That cancer is
due to a pathological interaction between tissues is not a
new claim; this was predicated by German pathologists
during the second half of the 19th century [23,24]. The
merits of both SMT and TOFT to explain carcinogenesis
have been debated elsewhere based on experimental,
clinical and theoretical grounds [6,7,25].
In the last decade, given the increasing lacks of fit
between the premises of SMT and the evidence gath-
ered from the huge amount of data generated by novel
technical improvements in gene sequencing, a merging
of the cell-based SMT and tissue-based components
has been proposed as an add-on to the original SMT
[11,18,26-28]. Based on grounds that SMT and TOFT
are centered on a) different levels of biological orga-
nization (cell for SMT, tissue for TOFT) and b) op-
posite premises regarding the proliferative default state
(quiescence for SMT and proliferation for TOFT), we
and others have argued against accepting this com-
promise [6,7,10,29,30]. Moreover, in addition to evi-
dence challenging the need for somatic mutations to
significantly participate in the carcinogenic process [31],
experimental and clinically-based evidence has docu-
mented that solid tumor carcinogenesis can occur in the
absence of somatic mutations [32,33]. Also, equally robust
experimental and clinical evidence shows that stromal
alterations lead to neoplasia of the parenchyma as exem-
plified in leukemia [34-36].As a result of the lacks of fit referred to above, another
variant of SMT has been proposed, namely, the cancer
stem cell (CSC) theory of carcinogenesis. Despite aggres-
sive efforts directed at identifying normal stem cells and
cancer stem cells, these entities remain as operational and
rather elusive concepts [37-39]. In addition, the stem cell
niche appears to be made up of epithelial cells plus the
adjacent stroma; under this perspective, stemness is
likely to be conferred by the niche and not by an au-
tonomous epithelial cell-based property [37,40]. Thus,
the CSC theory would represent another example of the
type of “compromise” theory (SMT plus a tissue-based
component) referred to above.
A pathogenetic classification of cancers
In Figure 1, we outline our proposed novel etiopathoge-
nic classification of cancers. It is comprised of two main
groups of tumors, namely, 1. Inborn errors of develop-
ment. Within this group, we identify 2 sub-groups of
neoplasms. First, there are 1A. Inborn inherited errors
of development - the result of a process initiated by a
germ-line mutation(s) in the genome of one or both
gametes (sperm and/or ovum). The mutated genome of
the resulting zygote will endow all the cells in the mor-
phogenetic fields of the developing organism with such
a genomic mutation(s). The altered expression of these
mutated genes could take place either during organo-
genesis, tissue remodeling and/or repair. This provides
a temporal-dependent dimension to the carcinogenic
process. Examples of this variety of inborn error of devel-
opment include retinoblastoma, Gorlin syndrome, xero-
derma pigmentosa, BRCA-1 and-2 neoplasia, and many
others (for a comprehensive listing and description of
these tumors see [41,42]).
Remarkably, King et al. [43] noticed in a cohort of
patients carrying BRCA mutations that breast cancer
risk by age 50 among carriers born before 1940 was
24%, whereas it was 67% among those born after 1940
[43]. These authors concluded that “non-genetic factors
may significantly influence the penetrance even of high-
penetrance mutations”. On the one hand, this evidence
argues in favor of identifying those non-genetic envir-
onmental factors - presumably due to exposure to pol-
lutants that significantly increase the cancer incidence
not only of inborn inherited errors of development, but
also of sporadic tumors. On the other hand, their ob-
servations strengthen the merits for postulating a novel
pathogenetic classification of neoplasms that would re-
flect a significant participation of the environment in
carcinogenesis.
Within the group of inborn errors of development, we
identify a second subgroup of neoplasms that we named
1B. Inborn induced errors of development (Figure 1).
As the name implies, tumors and/or malformations would
Figure 1 Novel pathogenetic classification of neoplasia. This classification distinguishes 2 main types of neoplasia as inborn errors of development
(A) and sporadic cancers (B). A is further classified into inborn errors of development that may be either inherited (a) or induced (b).
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by exposure to environmental chemicals, such as synthetic
hormones (Diethylstilbestrol (DES)) as well as by elevated
levels of endogenous hormones [44-46]. Exposure of ro-
dent embryos, fetuses and neonates to environmental es-
trogens generate premalignant and malignant neoplastic
lesions in diverse tissues later in life [47,48]. In humans,
exposure of fetuses to DES during the first trimester of
pregnancy, correlated with the appearance of vaginal clear
cell carcinomas during puberty and early adulthood. A
conclusive correlation between exposure to DES and clear
cell carcinoma was established because this rare neoplasmappeared in non-DES exposed populations only in post-
menopausal women [49]. Animal experiments showing
the development of adenosis, pre-neoplastic lesions con-
sidered precursors of clear cell carcinomas also suggests a
causal link between a synthetic estrogen, DES, and the
rare cancer described above [50]. Consistent with the ef-
fect of DES exposure in rats, there was an increased in-
cidence of breast carcinomas in the above-mentioned
cohort of women when they reached the prevalent age at
which breast cancer most commonly occurs [51,52].
Furthermore, reports increasingly indicate that envi-
ronmental chemicals are important causes in generating
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docrine disruptors (EED) that are defined as an exoge-
nous chemical, or mixture of chemicals, that interferes
with any aspect of hormone action [53]. For example,
Bisphenol-A (BPA) has been shown to increase the inci-
dence of hormone-related cancers in rodents [46]. EEDs
are suspected to be a factor in human breast and pros-
tate cancers over the last 50 years [47,54]. Because BPA
as well as other EEDs are not mutagens, the fact that
they induce cancer cannot be adequately explained by
the SMT, but is better understood from the TOFT per-
spective as due to faulty cell-cell and/or tissue-tissue in-
teractions [54,55]. It is in this context that we consider
cancer as “development gone awry”.
The World Health Organization’s cancer agency, IARC,
has extrapolated industrialization with damaging lifestyle
changes as also implying a correlation between direct
and/or indirect effects of greater exposure in and out of
the workplace (which includes pregnant women) to
noxious chemicals and higher cancer incidence [56,57].
Since the 2008 estimates, breast cancer incidence has
increased by more than 20% and mortality by 14%. Based
on these statistics, IARC subsequently acknowledged the
emergence of a “toxic epidemic” of cancers in developing
nations [58].
2. “Sporadic” tumors. Neoplasms due to germ-line
mutations have been considered to represent less than
5% of all cancers [42,59], whereas “sporadic” ones repre-
sent the vast majority of clinical cancers. The characteri-
zation of cancers as “sporadic” extends to any cancer that
appears to have no obvious link to germ-line mutations
(Figure 1). Their characteristics and properties have been
described in great detail in the biomedical literature and
will not be dealt with in this article. Our novel classifi-
cation anticipates, however, that many of what are now
considered as “sporadic” cancers will in the future be
reclassified as Inborn induced errors of development.
Briefly, the term “sporadic” cancers would now be re-
stricted to those cancers that result from carcinogenic
exposures after gestation.
Conclusions
A pathogenic classification of cancer is being proposed
based on novel insights on experimental carcinogenesis,
and from evidence collected through highly sophisti-
cated genome analysis in search of somatic mutations.
This classification identifies the presence of 2 major
groups of cancers, namely, 1) inborn errors of develop-
ment, and 2) “sporadic” ones. Based on whether or not
genomic mutations are responsible for the emergence
of a cancer tissue phenotype, the former group is fur-
ther classified into 1A) inborn inherited errors of devel-
opment and 1B) inborn induced errors of development.
This classification better reflects current views abouthow cancers develop, and anticipates that the incidence
of “sporadic” cancers now being diagnosed will dimi-
nish by being reclassified as our type 1B.
Endnote
aFor the sake of simplicity, we will use the nouns can-
cers, neoplasms and tumors interchangeably.
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